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Abstract
Mutations in myocyte enhancer factor 2C (MEF2C), an important transcription factor in neurodevelopment, are associated
with a Rett-like syndrome. Structural variants (SVs) upstream of MEF2C, which do not disrupt the gene itself, have also been
found in patients with a similar phenotype, suggesting that disruption of MEF2C regulatory elements can also cause a
Rett-like phenotype. To characterize those elements that regulate MEF2C during neural development and that are affected
by these SVs, we used genomic tools coupled with both in vitro and in vivo functional assays. Through circularized
chromosome conformation capture sequencing (4C-seq) and the assay for transposase-accessible chromatin using
sequencing (ATAC-seq), we revealed a complex interaction network in which the MEF2C promoter physically contacts
several distal enhancers that are deleted or translocated by disease-associated SVs. A total of 16 selected candidate
regulatory sequences were tested for enhancer activity in vitro, with 14 found to be functional enhancers. Further analyses
of their in vivo activity in zebrafish showed that each of these enhancers has a distinct activity pattern during development,
with eight enhancers displaying neuronal activity. In summary, our results disentangle a complex regulatory network
governing neuronal MEF2C expression that involves multiple distal enhancers. In addition, the characterized neuronal
enhancers pose as novel candidates to screen for mutations in neurodevelopmental disorders, such as Rett-like syndrome.
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Introduction
Myocyte enhancer factor 2C (MEF2C) is a member of the MADS
(MCM1, Agamous, Deficiens, and SRF (serum response factor))
family of transcription factors. The group of MEF2 transcription
factors (MEF2A, B, C and D) plays a pivotal role in regulating
myriad pathways during cell differentiation and organogene-
sis (1). These four MEF2 genes show, in both developing and
adult tissues, partially overlapping spatiotemporal expression
patterns. The highest expression levels are found in striated
muscles and brain (especially in cerebellum, cerebral cortex and
hippocampus) (2). MEF2C is the first MEF factor to be expressed
during development and plays a crucial role in muscle, heart,
craniofacial and neuronal development (1). Homozygous knock-
out mice show embryonic lethality due to cardiovascular defects
even before brain development takes off (3). However, a con-
ditional homozygous Mef2c deletion in radial glial cells during
late embryogenesis indicates an essential role in hippocampus-
dependent learning and memory by suppressing the number
of excitatory synapses and thereby regulating basal and evoked
synaptic transmission (4).
In the context of human disease, MEF2C has primarily been
associated with a severe intellectual disability syndrome that
shows phenotypic overlap with Rett syndrome (severe devel-
opmental delay, absence of speech, seizures, hypotonia and
stereotypic movements). The phenotypical similarities are likely
caused by the involvement of MEF2C in common pathways
with MECP2 and CDKL5, genes known to be involved in Rett
syndrome (5,6). Both structural variants (SVs) and point muta-
tions affecting MEF2C have been found in patients with Rett-
like features (5,7–12). To date, 49 cases with a 5q14.3 microdele-
tion have been reported, of which the majority encompass the
entire MEF2C gene. Partial gene deletions, as well as smaller
intragenic deletions,duplications andpointmutations,have also
been described, often being associated with a slightly milder
phenotype (7,9,13).
Interestingly, in addition to these aberrations directly
affecting the MEF2C protein-coding sequence, several deletions
and translocations in the region upstream of MEF2C have been
reported in patients with Rett-like manifestations (8,13–18).
Moreover, this region was recently shown to be enriched for
breakpoints of balanced chromosomal abnormalities (BCAs) in
a large cohort of patients with developmental anomalies (13).
In total, at least nine BCA breakpoints have been reported in
the region upstream of MEF2C, with some of these patients
also displaying a decreased MEF2C expression (13,14,17,18).
Altogether, this suggests that, in these cases in which MEF2C
itself remains unaffected, the Rett-like phenotype could be
attributed to the disruption of long-range interactions and
local chromatin reorganization, crucial to MEF2C transcriptional
regulation.
As MEF2C is an essential transcription factor, expressed in
a specific spatiotemporal manner, its transcriptional regulation
is complex and involves multiple tissue-specific regulatory ele-
ments (19–22). First, MEF2C contains three transcription start
sites (TSSs) with variable 5′ untranslated regions within a broad
promoter region. There are 11 coding exons spanning ∼100 kb
of genomic DNA which, due to alternative splicing, can be tran-
scribed into 6 human transcript variants. These alternatively
spliced MEF2C transcripts differ significantly in expression pat-
tern and transactivation functions, and some of them were
shown to be brain specific (5,23,24). In addition, two enhancers
that direct specific expression in neuronal crest cells have been
described previously (21). Despite the identification of a few reg-
ulatory elements, the examination of structural variants in the
5q14.3 region in individuals with a Rett-like syndrome suggests
that additional, yet undetected, distal neuronal enhancers in
the MEF2C locus could be crucial to MEF2C regulation (Fig. 1,
Table 1). Therefore, a comprehensive analysis of active neuronal
enhancers is required to fully elucidate the gene regulatory
landscape of the MEF2C locus.
To shed light on the regulatorymechanisms governingMEF2C
expression and aid the interpretation of chromosomal aber-
rations in the MEF2C regulatory region, we (1) examined all
previously reported SVs that were associatedwith Rett-like char-
acteristics in the region, (2) performed circularized chromosome
conformation capture sequencing (4C-seq) and the assay for
transposase-accessible chromatin using sequencing (ATAC-seq)
to identify interacting regulatory regions and integrated this
with epigenetic enhancer marks and evolutionary conserva-
tion to delineate putative regulatory elements, (3) evaluated the
enhancer activity of these elements in vitro using luciferase
assays and (4) determined their in vivo activity pattern using
zebrafish enhancer assays.
Results
Chromosomal aberrations compromise the MEF2C
regulatory region in individuals with Rett-like
syndrome
To get an overview of SVs with a putative regulatory impact in
theMEF2C region,wemined the literature and variant databases
in search of previously reported cases with chromosomal
aberrations at 5q14.3, in which the MEF2C-coding sequence was
not disrupted. We found 11 microdeletions, 8 translocations
and 1 inversion in individuals exhibiting Rett-like features
(global developmental delay, seizures, hypotonia, intellectual
disability or other neurological abnormalities) (Fig. 1A, Table 1)
(8,13–18,25). These SVs were located between 52 kb and 1.7 Mb
upstream of the MEF2C TSS and deletion sizes ranged from
314 kb to 37.7 Mb. While none of them encompasses MEF2C
itself, they are all situated within or overlap with the same
topologically associated domain (TAD), which spans >2 Mb and
contains seven genes in total. As MEF2C is situated near the left
TAD boundary, its regulatory region is probably located upstream
and delimited by the distal TAD boundary (Fig. 1A). Therefore,
disruption of this region by the selected variants is possibly
detrimental to MEF2C transcriptional regulation and could be
causative for the observed Rett-like phenotype.
The MEF2C promoter region physically interacts with
distal putative enhancer elements
To identify distal enhancer candidates that interact withMEF2C,
we performed 4C-seq with the MEF2C promoter as bait. We
captured MEF2C interactions in two cell lines with high MEF2C
expression: SH-SY5Y, a human cell line often used as a neuronal
model (26,27); and HEK293, a human embryonic kidney cell line,
as a non-neuronal control (Supplementary Material, Fig. S1).
In SH-SY5Y, the 4C profiles showed several distinct interacting
regions across the entire TAD (Fig. 1B, and Supplementary Mate-
rial, Fig. S2). Using the peak C algorithm,we called 14 interaction
loci (28). Remarkably, these interactions were completely absent
in HEK293 cells, despite a similar MEF2C expression level (Sup-
plementary Material, Fig. S2). To find additional evidence for the
presence of active regulatory elements within the interacting
loci, we mapped regions of active chromatin in SH-SY5Y cells
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Figure 1. MEF2C interacts withmultiple enhancer elements in its regulatory region. (A) TheMEF2C locus is disrupted in patients with a Rett-like phenotype. Black boxes
represent the local TAD structure, as found in the 3D Genome Browser (GM12878, 1 kb resolution) and delineate the MEF2C regulatory domain (51,52). Chromosomal
abnormalities, including 11 deletions (red bars) and 9 translocations (red arrows) in patients with a Rett-like phenotype, disrupt the MEF2C regulatory region without
affecting theMEF2C protein-coding sequence. (B) Chromatin interactions at the MEF2C locus determined by 4C-seq.The 4C-seq profile (RPM normalized and smoothed)
from SH-SY5Y (blue) shows MEF2C promoter interactions with multiple regions in the MEF2C TAD (triangle means viewpoint location). These interactions are notably
absent from the 4C interaction profile in HEK293 cells (green). 4C peaks called by the peak C algorithm are indicated below the profiles (dark blue/green is based on
two biological replicates; light blue/green, based on one of two biological replicates). Shown below are publicly available ChIP-seq data for histone marks H3K27Ac and
H3K4me1 in SH-SY5Y (tag count, normalized to 107 reads) (31), publicly available DNaseI-seq data for SK-N-SH (parental cell line of SH-SY5Y, read-depth normalized
signal) (30) and ATAC-seq data for SH-SY5Y (RPKM normalized signal). Putative enhancer loci selected for further analyses (e1–e16) are highlighted in green. (C) MEF2C
interaction network.All called 4C interactions (in SH-SY5Y) for theMEF2C promoter and all reciprocal viewpoints are plotted as transparent blue arches. Three heatmaps
reflect the distance between every region in the interaction network and the nearest DNaseI, H3K27Ac and H3K4me1 mark found in multiple human neuronal cell
types and brain tissues as determined through zipper plot analysis (32).
using the assay for ATAC-seq (29). We found a high degree of
overlap between the 4C peaks and the ATAC signal, as well as
with publicly available DNaseI-seq (30) and ChIP-seq data for
enhancer-associatedmarks (H3K27Ac andH3K4me1) (31) (Fig. 1B
and Supplementary Material, Fig. S4).
To verify the most prominent interactions identified in
SH-SY5Y, we performed reverse 4C experiments using seven
selected interacting regions, i.e. reciprocal viewpoints, as bait
(Supplementary Material, Figs S2 and S3). The resulting 4C
profiles confirmed the interaction of these reciprocal viewpoints
with the MEF2C promoter region. Next, we assessed whether
these interacting regions could harbor regulatory elements.
Using zipper plot analysis, we determined the distance of
all peaks called on SH-SY5Y 4C data sets to three epigenetic
enhancer features (DNaseI hypersensitivity, H3K27Ac and
H3K4me1) in human brain tissues (Supplementary Material, Fig.
S5C) (32).We found that∼60–80%of called 4C peaks residewithin
5 kb of these enhancer features. Moreover, when comparing
the shape of 4C peak zipper plots with those of equal sets of
randomly generated coordinates (within the MEF2C TAD) and in
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Table 1. Structural variants in the MEF2C regulatory region.
Location Type Phenotype Reference
chr5:88412388-91996699 Deletion Severe ID, seizures and hypotonia Engels et al. (2009) (8)
chr5:88605645-94850706 Deletion Developmental delay, seizures, hypotonia,
macrocephaly and heterotopia
Cardoso et al. (2009) (15)
chr5:88833718-94826030 Deletion Moderate ID, severe ADHD, iris coloboma,
hearing loss, dental anomaly and
dysmorphic facial features
Sobreira et al. (2009) (16)
chr5:89909319-105901597 Deletion Developmental delay, cranial and facial
dysmorphia, seizures, hypotonia and
heterotopia
Cardoso et al. (2009) (15)
chr5:88232587-93437723 Deletion Developmental delay, seizures and
hypotonia
Kaminsky et al. (2011) (25)
chr5:88348147-88783092 Deletion Developmental delay and/or other
significant developmental or
morphological phenotypes
Kaminsky et al. (2011) (25)
chr5:88377169-104022949 Deletion Developmental delay, seizures, heterotopia
and coloboma
Kaminsky et al. (2011) (25)
chr5:89523963-90412409 Deletion Developmental delay and/or other
significant developmental or
morphological phenotypes
Kaminsky et al. (2011) (25)
chr5:89670423-127412115 Deletion Abnormality of cranial structures,
overlapping fingers and toe and Tetralogy
of Fallot
Kaminsky et al. (2011) (25)
chr5:89208994-89855436 Deletion ID and myopathy Kaminsky et al. (2011) (25)
chr5:89453519-89767052 Deletion Abnormality of the cerebral white matter
and autism
Kaminsky et al. (2011) (25)
chr5:88300578-88300579 Translocation Severe ID and seizures Saitsu et al. (2011) (17)
chr5:88400843-88400848 Inversion Developmental delay, seizures, hypotonia
and autism
Redin et al. (2017) (13)
chr5:88595584-88597509 Translocation ID Vergult et al. (2014) (18)
chr5:88706882-88706887 Translocation ID, seizures, hypotonia and sensorineural
deafness
Redin et al. (2017) (13)
chr5:88756256-88756239 Translocation Prenatal case; partial agenesis of corpus
callosum and ventriculomegaly
Redin et al. (2017) (13)
chr5:88793025-88793026 Translocation Developmental delay Redin et al. (2017) (13)
chr5:88742810-88742811 Translocation Developmental delay and autism Floris et al. (2008) (14)
chr5:88829562-88829564 Translocation Developmental delay, seizures, hypotonia
and dysmorphic facial features
Redin et al. (2017) (13)
chr5:89055499-89055498 Translocation Developmental delay, microcephaly and
dysmorphic features
Redin et al. (2017) (13)
Structural variants found in patients with Rett-like characteristics, situated in or overlapping the MEF2C TAD, without disrupting the MEF2C protein-coding sequence
ID = Intellectual Disability.
vivo validated brain enhancers (33), the 4C zippers tend much
more toward the known brain enhancer zippers, suggesting that
our 4C data indeed identified regions containing brain enhancer
elements (Supplementary Material, Fig. S5C).
Integrating all called interactions (MEF2C promoter and all
tested reciprocal viewpoints) found in SH-SY5Y, we identified 69
interaction peaks within the MEF2C TAD. Interestingly, several
interacting regions seemed to be present in multiple 4C data
sets. This indicates that, besides contacting theMEF2C promoter,
these putative regulatory regions interact with each other as
well, forming a regulatory network that contains multiple inter-
action nodes (Fig. 1C). The peak regions present in this network
are more conserved than randomly selected intervals within the
MEF2C region and are all within close proximity to enhancer
marks (H3K4me1, H3K27Ac and DNaseI hypersensitivity) in the
human brain (Fig. 1C, Supplementary Material, Fig. S5A and B).
To conclude, theMEF2C promoter is involved in a complex inter-
action network, containing multiple regions, which indicates
that the coordinated action of multiple enhancer elements is
required for the precise spatiotemporal regulation of MEF2C.
MEF2C interacting regions harbor regulatory elements
with in vitro enhancer capacity
To characterize the activity of putative enhancer elements that
interact with the MEF2C promoter, we delineated 16 enhancer
candidates (e1–e16), within the 7 interacting regions we vali-
dated using reverse 4C. The 16 putative enhancers were selected
based on the presence of conserved sequence stretches and
human brain enhancers as inferred by the ROADMAP and FAN-
TOM consortia (Supplementary Material, Fig. S6).We tested their
capacity to enhance target gene expression in vitro, in both
HEK293 and SH-SY5Y cells, using luciferase assays.
In the context of HEK293 cells, 10 out of 16 tested enhancer
candidates were able to significantly increase luciferase activity
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Figure 2. MEF2C enhancers display distinct activity patterns. (A) In vitro enhancer activity of candidate elements. Log2 luciferase activity relative to a negative control
(NC) vector, in HEK293 (left) and SH-SY5Y (right), for 16 putative enhancer elements (linear mixed effects model, log2 enhancer effect fold change (FC) ± standard
error). Green means significant positive effect (P < 0.01); blue, significant negative effect (P < 0.01); grey, no significant (NS) effect. (B) Enhancer activity in HEK 293
versus SH-SY5Y cells. Log2 of the relative luciferase activity in HEK293 versus SH-SY5Y cells. (C) Tissue-specific enhancers in zebrafish embryos at 24 and 48 hpf.
Eight enhancers induce neuro-specific GFP expression: e1 and e2 in the forebrain and specific peripheral neurons; e3 in the middle of the notochord at 24 hpf; e4 in
the forebrain, specific neurons above the eye, somitic muscles and heart; e7 in the forebrain and notochord at 24 hpf; e9 in neurons with vertical projections in the
midbrain/hindbrain and spinal cord at 24 hpf e12 drove general GFP expression in the central nerve system, including the head, tail and trunk at 24 hpf; and e15 in the
forebrain and notochord at 48 hpf. The color code reflects the observed activity of the 16 tested candidate enhancer elements: green means active in neuronal tissues;
blue, active in other than neuronal tissues; white, not active.
over a negative control vector (Fig. 2A; Supplementary Mate-
rial, Fig. S7 and Tables S6–S9). However, several enhancers only
marginally increased luciferase expression and one region (e12)
even resulted in a significantly diminished activity. Since we
selected these candidate enhancer regions based on interactions
in SH-SY5Y, we hypothesized that the absence or presence of
specific transcription factors could have influenced the activity
of the selected elements in HEK293. Therefore, we performed
the same luciferase assays in SH-SY5Y cells (Fig. 2A; Supple-
mentary Material, Fig. S7 and Tables S6–S9).The overall activity
of the candidate enhancers was higher in SH-SY5Y than in
HEK293 (Fig. 2B). In total, 14 candidate enhancers significantly
increased luciferase expression, with the enhancer-like CETN3
promoter region (e16) even resulting in a 57-fold increase over
the control vector. Remarkably, some candidates (e.g. e4, e5,
e12 and e14) even showed a radically different activity pattern
in both cell lines, underscoring that a specific transcription
factor repertoire could be required for the function of these
enhancers. In conclusion, themajority of the selected candidates
displayed enhancer capacity in in vitro enhancer assays, with in
many cases a higher activity being observed in SH-SY5Y than in
HEK293.
MEF2C regulatory elements show in vivo neuronal
enhancer activity
Next,we characterized the in vivo activity pattern of the 16 candi-
date enhancer elements using a zebrafish model. The enhancer
candidate sequences were cloned into a zebrafish enhancer
assay vector, containing an E1b minimal promoter followed by
the green fluorescent protein (GFP) reporter gene (34). These vec-
tors were microinjected into one-cell stage zebrafish embryos
alongwith the Tol2 transposase to facilitate genomic integration.
GFP expression was monitored at 24, 48 and 72 h post fertiliza-
tion (hpf).
Eleven sequences showed consistent GFP expression (≥30%
of GFP expressing embryos) in specific tissues (Supplementary
Material, Table S4). Eight enhancers (e1, e2, e3, e4, e7, e9, e12 and
e15) exhibited neuro-specific activity, in concordance with pre-
viously describedMef2c expression patterns (Fig. 2C and Supple-
mentary Material, Fig. S8) (35,36). e1 and e2 drove GFP expression
in the forebrain and specific peripheral neurons. The activity of
these enhancers is specific to bilateral neurons above the eye
that project along the trunk at 24, 48 and 72 hpf (Fig. 2C and
Supplementary Material, Fig. S8). e3 drove GFP expression at the
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middle of the notochord at 24 hpf and expanded to the entire
notochord at 48 and 72 hpf (Fig. 2C and Supplementary Material,
Fig. S8). Not only e4 was active in the forebrain and specific
neurons above the eye at 24–72 hpf, mimicking the activity of
e1 and e2, but also it drove GFP expression in somitic muscles
and the heart. e7 drove GFP expression in the forebrain and
notochord at 48 and 72 hpf. e9 showed activity in the midbrain,
hindbrain and spinal cord at 48 and 72 hpf. The enhancer is
active in neurons with vertical projections in midbrain and
hindbrain. e12 drove general GFP expression in the central nerve
system at 24 hpf. The enhancer shows activity in the head, tail
and trunk at 24–72 hpf. e15 drove specific GFP expression in the
forebrain and notochord at 24 hpf that was reduced at 48 hpf and
totally eliminated at 72 hpf. In addition, e6 and e13 showed spe-
cific expression in the heart at 48 hpf (Supplementary Material,
Fig. S8) and the enhancer-like promoter, e16, directed expression
in the epithelial of the head at 24 hpf (Supplementary Material,
Fig. S8). In conclusion, the zebrafish enhancer assay identified
five forebrain enhancers (e1, e2, e4, e7, e12 and e15), one mid /
hindbrain enhancer (e9), three enhancers with specific activity
in neurons above the eye that project to the trunk (e1, e2 and
e4) and three notochord enhancers (e3, e7 and e15). Altogether,
these enhancers may regulate MEF2C expression during central
nervous system development.
Discussion
Previously, only a few (intragenic) MEF2C enhancers had been
identified and some single, close-range interactions with the
MEF2C promoter had been tested (21,37), leaving it hitherto
impossible to evaluate the suspected functional impact of SVs in
the MEF2C region. Here, however, we presented a first thorough
overview of MEF2C interactions, enhancer elements and their
activities.
Through 4C-seq in a neuronal cell line, we found that the
MEF2C promoter engages in long-range interactions with several
distal loci, some located as far as 2 Mb upstream and many of
which are situated within open and active chromatin (deter-
mined by ATAC-seq). These interactions are notably confined
to the MEF2C TAD, as reflected by the rapidly decreasing 4C
coverage beyond the TAD boundaries, and do not appear to be
ubiquitously present across cell lines, since they are absent in
HEK293 cells. Moreover, we have shown that, similar to known
brain enhancers, almost all of these interacting regions are
situated in close proximity to enhancer-associated epigenetic
marks identified in brain tissues. This implicates that, while we
have only identified them in a neuronal model cell line, these
regions also harbor active regulatory elements in true neuronal
cells and tissues.
By gathering all detected interactions in the MEF2C locus,
it becomes clear that several enhancer loci interact not only
with the MEF2C promoter but also with other enhancer regions
and promoters within the TAD. For instance, the region that
encompasses neuronal enhancer e7 interacts with both the
MEF2C promoter and putative enhancers e11–e15. In this way,
a MEF2C interaction network is revealed, comprising the MEF2C
promoter, multiple distal sites harboring validated neuronal
enhancers and other putative regulatory elements such as
the enhancer-like promoter of CETN3. This network greatly
extends upon previously identified regulatory interactions in
the proximal region upstream ofMEF2C (37). Although this inter-
action network is yet to be fully completed, it clearly suggests
that the MEF2C promoter is involved in a complex chromatin
organization, probably required for the precise regulation of
MEF2C.
The majority of the selected interacting enhancer regions
show in vitro enhancer activity. Interestingly, we observed clear
differences in their activities between a neuronal and non-
neuronal cell line, suggesting that a specific transcription factor
repertoire is required for enhancer activity. Further research will
be necessary to identify the transcription factors essential for
the activity of the selected enhancers in neuronal cells. Eleven
enhancers display distinct activity patterns (eight neuronal and
three non-neuronal) during zebrafish development. Together,
these might regulate MEF2C transcription in a specific spa-
tiotemporal manner. However, several enhancers also show
overlapping activity (e.g. e1, e2, e4, e7 and e12 are active in
the forebrain), probably ensuring a robust MEF2C expression,
essential to normal development. Further investigation will
be required to elucidate the exact mode of action of these
enhancers. Not all of the tested enhancer candidates were found
to be active, although it is likely that a few of them are active but
were not detected due to the use of a generic minimal promoter
(e.g. e1b promoter for zebrafish) or because these sequences
were taken out of context. Nevertheless, the identification of
these neuronal MEF2C enhancers should provide a starting
point to assess the functional implications of aberrations in the
MEF2C region. Four elements (e8, e13, e15 and e16) were already
included in a targeted screen for damaging de novo mutations
in 6000 exome-negative patients with developmental disorders
(38). Although only a small fraction (0.15%) of de novo enhancer
mutations cause neurodevelopmental disorders through a
dominant mechanism, the enhancers we identified should be a
valuable addition to such screens as they have similar character-
istics (conserved and with neuronal activity) as enhancers that
were shown to be enriched in damaging de novo mutations (38).
Hitherto, at least 20 SVs affecting theMEF2C regulatory region
without disrupting MEF2C have been described in the litera-
ture or are present in variant databases. Clinical features often
include developmental delay, seizures, hypotonia, intellectual
disability and characteristics they have in commonwith the pre-
viously described Rett-likeMEF2C syndrome.We found deletions
ranging from 314 kb to 37.7 Mb, some falling completely within
the MEF2C TAD, some crossing the TAD boundary, extending
for megabases upstream ofMEF2C and comprising several other
genes and putative regulatory elements.Although, for these very
large deletions, deletion of other genes probably contributes
to the aberrant phenotype, also for the smaller deletions and
balanced aberrationswe could not find a correlation between the
severity of the reported phenotype and the number of deleted or
translocated enhancers. However, as most translocation break-
points are situated in the region between e6 and e7, it appears
that the presence of the more proximal enhancers alone is
not sufficient for correct MEF2C regulation and that the distal
region contains some crucial neuronal enhancers. Moreover,
some smaller deletions contain only a few enhancers, suggesting
that the entire regulatory region is probably required for correct
MEF2C regulation.
In summary, MEF2C has a pivotal role in neuronal devel-
opment and MEF2C haploinsufficiency manifests as a Rett-like
syndrome featured by severe intellectual disability, seizures and
stereotypic movements. The MEF2C promoter interacts with
multiple distal neuronal enhancers in its upstream region and
the disruption of these interactions by chromosomal abnormal-
ities could lead to haploinsufficiency in early brain development
and result in a similar phenotypic outcome as MEF2C coding
mutations.
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Materials and Methods
Cell culture. All cell lines were cultured in complete RPMI 1640
medium (FBS, 10%; P/S, 1%; glutamine, 1%; kanamycine, 1%).
Cells were passaged every 3–4 days. We allowed at least two
passages before using cells in experiments.
RNA isolation, cDNA synthesis and quantitative PCR. Total RNA
was extracted using TRIzol (Invitrogen #15596026; Thermo Fisher
Scientific, Waltham, MA, USA) and the RNAeasy kit (Qiagen
#217004; Qiagen, Venlo, The Netherlands). Complementary DNA
(cDNA) synthesis was performed using the iScript cDNA synthe-
sis kit (Bio-Rad #170-8891; Bio-Rad, Hercules, California, USA).
Quantitative polymerase chain reaction (qPCR) was performed
using 2× SYBR Green SsoAdvanced Supermix (Bio-Rad #172-
5274) with 5 μm forward and reverse primer and 5 ng cDNA
input. Expression values were analyzed using qBase + software
(Biogazelle, Ghent, Belgium) and normalized using three refer-
ence genes (GAPDH, SDHA and UBC). All primer sequences can
be found in Supplementary Material, Table S5.
Preparation of 4C templates and sequencing libraries. The 4C
templates were prepared according to the protocol by Van de
Werken et al. (39). In brief, for each template 1 × 107 cells were
detached, counted, resuspended and cross-linked by incubating
them with 2% formaldehyde for 10 min at room temperature.
Following cell lysis, cross-linked DNA was digested with 400U
of DpnII restriction enzyme (NEB #R0543L; NEB, Ipswich,
Massachusetts, USA) and nearby DNA fragments were ligated
using 50U of T4 DNA ligase (Roche #10799009001; Merck,
Darmstadt, Germany). Ligated DNA circles were de-cross-linked
overnight using proteinase K and purified with NucleoMag
P-Beads (Macherey-Nagel, Düren, Germany) to obtain an
intermediate 3C template. A second round of digestion and
ligation, using 50U of Csp6I restriction enzyme (Thermo Sci-
entific #ER0211; Thermo Fisher Scientific, Waltham, MA, USA),
resulted in 4C templates.
Adaptor-containing reading and non-reading primers, spe-
cific to the viewpoints of interest, were designed to amplify all
captured, interacting DNA fragments (Supplementary Material,
Tables S1 and S2) (39). For each viewpoint, 16 PCR reactions, each
using 200 ng of input 4C template, were pooled. Resulting 4C-
sequencing libraries were purified using High Pure PCR Product
Purification kit (Roche #11732676001) and QIAquick PCR Purifi-
cation kit (Qiagen #28106).
4C sequencing and analysis. Approximately 15 to 20 different
4C sequencing libraries were pooled and sequenced simulta-
neously on an Illumina NextSeq 500 (single-end, 75 nt, load-
ing concentration 1.6 pM). Sequencing libraries were demulti-
plexed based on the presence of the viewpoint-specific reading
primer sequence, which precedes the captured DNA sequence.
Following removal of these reading primer prefixes, captured
sequences were mapped to the hg19 reference genome using
Bowtie2 (40). For the cis chromosome,mapped read counts were
summarized per DpnII restriction fragment. Finally, 4C coverage
profiles were obtained by normalizing the per fragment coverage
to reads permillion (RPM) on the cis chromosomeand smoothing
the normalized coverage using the rollmean function from the
R ‘zoo’ package with a window size of 21 fragments (41). 4C
peaks were called using the peak C algorithm (28), based on two
biological replicates, except for reciprocal viewpoint 2 for which
only one replicate was available. The parameter settings used
were wSize = 21, alphaFDR = 0.2 and qW = 0.5.
4C peak conservation. PhastCons conservation scores for chro-
mosome 5 were retrieved from University of California Santa
Cruz (UCSC; http://genome.ucsc.edu/) (42,43). These scores were
used to calculate an average conservation score per nucleotide
in 4 kb windows surrounding all called 4C peak centers and
1000 random coordinates within theMEF2C TAD (chr5:87300000-
90700000, hg19).
4C peak zipper plot analyses. We used zipper plots (32) to
evaluate the overlap of our set of SH-SY5Y 4C peaks with data
for enhancer-associated epigenetic marks generated by the
ROADMAP Epigenomics Consortium (44). Zipper plots provide a
visual way of assessing the proximity of loci of interest to a wide
range of epigenetic features in a multitude of tissues, by tapping
into publicly available data from the FANTOM (45) and ROADMAP
consortia.We used all 69 SH-SY5Y 4C peaks as input and queried
enhancer marks, H3K4me1, H3K27Ac and DNaseI hypersensitiv-
ity, identified by the ROADMAP consortium in multiple human
neuronal cell types or brain tissues. The samples included
were cortex derived primary cultured neurospheres, ganglion
eminence derived primary cultured neurospheres, brain angular
gyrus, brain anterior caudate, brain cingulate gyrus, brain
germinal matrix, brain hippocampus middle, brain inferior
temporal lobe, brain dorsolateral pre-frontal cortex, brain
substantia nigra, fetal brain male and fetal brain female. The
same zipper plot analysis was performed for an equally large set
of random coordinates within the MEF2C TAD (chr5:87300000-
90700000, hg19, seed set to 1) and in vivo validated brain
enhancers from the VISTA Enhancer Browser (33).
Assay for ATAC-seq. ATAC-seq was performed as previously
described with minor changes (29). In short, 50 000 cells were
lysed and fragmented using 1% digitonin and Tn5 transposase
(Illumina, San Diego, California, USA). Next, the samples were
purified using the MinElute kit (Qiagen). The transposased DNA
fragments were amplified using 13 PCR cycles and purified
using Agencourt AMPure XP beads (Beckman Coulter, Brea, Cal-
ifornia, USA). ATAC-seq libraries were paired-end sequenced
on the NextSeq 500 platform (Illumina) using the Nextseq 500
High Output kit V2 150 cycles (Illumina). The ATAC files were
aligned to the human reference genome (hg19) using STAR (46)
with default parameters and blacklisted genomic regions were
excluded.ATAC-seq peakswere called usingMACS2with param-
eters –nomodel and –nolambda. The overlap of these peaks with
enhancer marks in SH-SY5Y cells (H3K4me1 and H3K27Ac) and
brain tissues (DNaseI, H3K27Ac and H3K4me1) was determined
using deepTools’ plotHeatmap function and zipper plots, respec-
tively (32,47).
Enhancer region delineation. We narrowed down enhancer
regions for further characterization based on conservation
and/or the presence of predicted enhancer elements by the
ROADMAP or FANTOM consortium (42,44,48). PhastCons conser-
vation scores, enhancer elements called by the FANTOM consor-
tium throughCAGE-seq and chromatin state segmentation for 11
neuronal cell lines or brain tissues by the ROADMAP consortium,
were accessed through the UCSC genome browser (43).
Luciferase enhancer assays. Selected, putative enhancer se-
quences (SupplementaryMaterial, Table S3) were amplified from
human genomic DNA (Roche #11691112001) and subsequently
cloned into the pGL4.24 firefly luciferase reporter vector
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(Promega #E8421; Promega, Madison, Wisconsin, USA) using
either standard restriction ligation cloning or Gibson Assembly
(NEB #E2611L). The constructed enhancer luciferase vectors
(100 ng) were cotransfected with the Renilla luciferase control
vector pRL-TK (5 ng, Promega #E2241) in HEK293 cells (96-well
format, seeding density 10 000 cells/well, 24 h pre-transfection)
using 0.3 μl lipofectamine 3000 (Thermo Fisher #L3000001) per
well. For transfection of vectors into SH-SY5Y, we used either
0.5 μl lipofectamine 3000 (96-well format, seeding density 25 000
cells/well, 24 h pre-transfection) or Neon nucleofection (Thermo
Fisher #MPK10025) (96-well format, seeding 60 000 transfected
cells per well). Each experiment was at least performed in
triplicate with six technical replicates per experiment. Enhancer
activity was determined 24 h post transfection using a Dual-
Luciferase Reporter Assay (Promega #E1910). Replicates for
which the signal did not exceed background (less than two
standard deviations above the mean background) were filtered
out and excluded from the analysis. Firefly luciferase activity
per well was normalized to Renilla luciferase activity. A negative
control luciferase vector with a ∼1500 bp insert was used as
reference. For each candidate enhancer, we determined the
effect on luciferase activity using a linear mixed effects model (R
‘lme4’ package (49)) with luciferase vector as fixed and biological
replicate as random effect. P-values were obtained by likelihood
ratio tests of themodel with the fixed effect against a null model
without this effect.
Transgenic zebrafish enhancer assays. Primers were designed
to amplify the candidate enhancer sequences from human
genomic DNA (Supplementary Material, Table S3). PCR products
were cloned into the E1b-GFP-Tol2 enhancer assay vector
containing an E1bminimal promoter followed by GFP (34). These
constructs were injected to zebrafish embryos using standard
procedures. For statistical significance, at least 100 embryos
were injected per construct in at least two different injection
experiments along with Tol2 mRNA to facilitate genomic
integration (50). GFP expression was observed and annotated
at 24, 48 and 72 hpf (Supplementary Material, Table S4). An
enhancer was considered a positive enhancer when 30% of the
alive embryos showed a consistent GFP expression pattern.
Data availability. The 4C data reported in this paper was
deposited in NCBI’s Gene Expression Omnibus (GEO) with
accession number GSE121549 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE121549).
Supplementary Material
Supplementary Material is available at HMG online.
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